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Structurally related tetratricopeptide repeat motifs
in steroid receptor-associated immunophilins and the
STI1 homolog, Hop, mediate the interaction with a com-
mon cellular target, hsp90. We have identified the bind-
ing domain in hsp90 for cyclophilin 40 (CyP40) using a
two-hybrid system screen of a mouse cDNA library. All
isolated clones encoded the intact carboxyl terminus of
hsp90 and overlapped with a common region corre-
sponding to amino acids 558–724 of murine hsp84. The
interaction was confirmed in vitro with bacterially ex-
pressed CyP40 and deletion mutants of hsp90b and was
delineated further to a 124-residue COOH-terminal seg-
ment of hsp90. Deletion of the conserved MEEVD se-
quence at the extreme carboxyl terminus of hsp90 pre-
cludes interaction with CyP40, signifying an important
role for this motif in hsp90 function. We show that CyP40
and Hop display similar interaction profiles with hsp90
truncation mutants and present evidence for the direct
competition of Hop and FK506-binding protein 52 with
CyP40 for binding to the hsp90 COOH-terminal region.
Our results are consistent with a common tetratricopep-
tide repeat interaction site for Hop and steroid receptor-
associated immunophilins within a discrete COOH-ter-
minal domain of hsp90. This region of hsp90 mediates
ATP-independent chaperone activity, overlaps the
hsp90 dimerization domain, and includes structural el-
ements important for steroid receptor interaction.
Peptidyl-prolyl isomerases are cellular proteins that can me-
diate changes in protein conformation by catalyzing cis-trans
isomerization about amino acid-proline peptide bonds (1–3).
Immunophilins represent the predominant group within the
rapidly growing peptidyl-prolyl isomerase protein family that
includes the cyclophilins and FK506-binding proteins (FK-
BPs)1 identified as cellular targets for the immunosuppressant
drugs cyclosporin A and FK506, respectively (4, 5). An overlap
of ligand binding and catalytic domains in immunophilins re-
sults in an inhibition of isomerase activity in response to im-
munosuppressant drug interaction (4, 5).
Cyclophilin 40 (CyP40) was first isolated and identified in
association with the unactivated estrogen receptor (6) and
shares structural and sequence homology with FKBP52, previ-
ously described as a common component of aposteroid receptor
complexes (7, 8). A third mammalian immunophilin, FKBP51,
with significant identity to CyP40 and FKBP52, has recently
been identified in the progesterone receptor complex (9). The
structural similarity among CyP40, FKBP51, and FKBP52 is
characterized by an amino-terminal immunophilin-like domain
and a conserved carboxyl-terminal tetratricopeptide repeat
(TPR) domain that mediates protein interaction (6, 9–12).
Within steroid receptor complexes the immunophilins bind
competitively to heat shock protein hsp90 to form distinct im-
munophilin-hsp90-receptor complexes (9, 13, 14). Conserved
structural features that determine immunophilin interaction
with an identical site in hsp90 include the TPR domain to-
gether with adjacent subregions located at the amino- and
carboxyl-terminal ends of the TPR domain, respectively (14,
15). Despite the overall similarities between these immunophi-
lins, there is accumulating evidence that they possess unique
structural elements allowing distinct interactions with hsp90,
leading to differential responses of receptor function (9, 15, 16).
The dynamic assembly of steroid receptors to a high affinity
hormone binding conformation requires the cooperative inter-
action of the major chaperones hsp70 and hsp90 (17–24; for
review, see Ref. 25). Newly synthesized receptor undergoes
sequential refolding through reactions mediated by hsp70, in
concert with regulatory influences from the co-chaperones
hsp40, Hip, and Hop, leading to the formation of receptor-
hsp70-hsp90 complexes (23, 26–29). The conformation state
and chaperone function of hsp70 and hsp90 are controlled by
nucleotide binding (29–38). Hop provides the essential link
between hsp70 and hsp90 and binds the chaperones simulta-
neously through favored interactions with ADP-bound forms of
both proteins (37). In what is likely to be a highly dynamic
setting, Hop enhances the efficient transfer of receptor sub-
strate from hsp70 to hsp90 (28). After dissociation of Hop and
hsp70, ATP-dependent conversion of hsp90 to the ATP-bound
conformer promotes recruitment of p23 and one of the immu-
nophilins to generate mature receptor complexes (23–25, 28).
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Although a precise role for p23 and the immunophilins in
receptor complexes has yet to be defined, evidence that these
accessory proteins are capable of independent chaperone activ-
ity (39, 40) raises the possibility that they might modulate
receptor function either directly or indirectly via hsp90.
The majority of accessory proteins that participate in the
chaperone-mediated assembly of steroid receptors possess
structurally related TPR motifs that mediate their interaction
with hsp90 and/or hsp70 (11–14, 22, 41, 42). Thus, in addition
to the large immunophilins, TPR units have been identified in
the hsp70-binding protein Hip (29), and six repeats are present
in the chaperone cofactor Hop (41, 43). Distinct TPR domains
located in the NH2- and COOH-terminal regions direct the
simultaneous interaction of Hop with hsp70 and hsp90, respec-
tively (22, 41). The ability of Hop to compete effectively with the
immunophilins for hsp90 binding (44), together with similar
observations with PP5, a serine protein phosphatase recently
identified as an additional component of the unactivated glu-
cocorticoid receptor (42), have led to suggestions of a common
TPR interaction site within hsp90 (44).
Genetic studies in yeast have confirmed that hsp90 is an
essential component for the activity of diverse intracellular
signaling molecules including steroid receptors and regulatory
tyrosine kinases involved in cell cycle control (for review, see
Ref. 25). A role for CyP40 in hsp90 regulatory function has been
demonstrated by studies in which deletion of Cpr7, a Saccha-
romyces cerevisiae homolog of CyP40, resulted in greatly re-
duced activities of both glucocorticoid and estrogen receptors
and pp60v-src kinase expressed in yeast (45).
To date one of our approaches to determining the function of
CyP40 and its partner immunophilins has been to study their
in vitro interaction with the known chaperone components of
steroid receptor complexes. In this way we have identified
hsp90 (14) and hsp702 as major cellular targets for CyP40
interaction. As an extension of this approach, we have begun to
use the yeast two-hybrid system (46) to search for additional
protein targets for CyP40. The modular domain structure of the
large immunophilins (6, 12, 47) makes it attractive to use these
domains separately as probes for protein interaction. In this
way the immunophilin domain of FKBP52 has been used suc-
cessfully in a yeast two-hybrid screen to isolate FAP48, a novel
protein that may represent a common natural ligand for FK-
BPs (48).
Here, we show that use of the yeast-based genetic assay, in
combination with the COOH-terminal TPR domain of CyP40
(amino acids 185–370), led predominantly to the isolation of
interacting clones that corresponded to hsp90 cDNAs encoding
the COOH-terminal dimerization domain of hsp90. In vitro
binding assays with deletion mutants of this region located the
interaction site for CyP40 to a 124-residue COOH-terminal
segment of hsp90 and confirmed that this region incorporates
the common TPR binding site for the immunophilins and Hop.
Deletion of the acidic EEVD motif, conserved at the carboxyl
terminus of hsp90 proteins, precluded CyP40 and Hop interac-
tion, consistent with a regulatory role of this microdomain in
hsp90 function.
EXPERIMENTAL PROCEDURES
Plasmids—pBTM116-CyP40 185–370 contains the carboxyl half of
CyP40 fused in-frame to the DNA binding domain of LexA (amino acids
1–202). The COOH-terminal portion of human CyP40, encoding resi-
dues 185–370, was amplified by PCR using primers that introduced an
EcoRI site at the 59-end and a termination codon with an EcoRI site at
the 39-end. Subcloning of this fragment into pGEM 3Z (Promega) at the
EcoRI restriction enzyme site allowed confirmation of sequence integ-
rity by automated sequence analysis (Applied Biosystems). The EcoRI
fragment was then ligated into the corresponding restriction site in the
bait vector pBTM116 (49), in-frame with the LexA DNA binding domain
to give pBTM116-CyP40 185–370.
The plasmid for the protein GST-bCyP40 WT has been described
(14). For untagged wild-type bovine CyP40, a bCyP40 cDNA template
was amplified by PCR using sequence-specific oligonucleotide 59- and
39-primers containing NdeI and BamHI restriction enzyme sites, re-
spectively. A TGA stop codon was placed immediately before the BamHI
site. The PCR fragment was ligated into pGEM-T (Promega), and the
sequence integrity of both ends of the insert in an isolated clone was
confirmed by automated sequence analysis (Applied Biosystems). An
XhoI to BclI fragment excised from a wild-type bCyP40 cDNA was
replaced to eliminate PCR-generated errors within this region. A full-
length bCyP40 fragment produced by NdeI and BamHI digestion was
then cloned into the pET-11 plasmid vector. The pET-11-bCyP40 WT
expression plasmid was transformed into the E. coli expression host
BL21(DE3). Overexpression of wild-type bovine CyP40 was induced by
0.4 mM IPTG, and lysates of recombinant CyP40 were prepared as
described below. Expression plasmids for human hsp90b (50), FKBP52
(10), and Hop were kindly provided as gifts by C. T. Walsh, D. A.
Peattie, and D. F. Smith, respectively. An identical cloning strategy was
used to generate NH2-terminal His-tagged expression plasmids for
hsp90b deletion mutants incorporating codons 530–724, 581–724, 600–
724, 530–700, and 530–719. Each construct was PCR amplified from
pET-15b-hsp90b (50) full-length cDNA template using Taq DNA polym-
erase with primers that introduced an NdeI site at the 59-end and a
termination codon with an NdeI site at the 39-end. The PCR fragment
was ligated into pGEM-T and was then excised with NdeI digestion
from a suitable clone confirmed for sequence fidelity. The gel-purified
fragments were cloned into the pET-28a(1) vector that had been lin-
earized with NdeI to give the expression plasmids pET-28a(1) 530–
724b, pET-28a(1) 581–724b, pET-28a(1) 600–724b, pET-28a(1) 530–
700b, and pET-28a(1) 530–719b.
The expression plasmid pET-28a(1) 589–732a was prepared for the
NH2-terminal His-tagged hsp90a deletion mutant encompassing resi-
dues 589–732. The plasmid was derived by PCR from a full-length
human hsp90a cDNA template (51) (kindly provided K. Yokayama)
using Pfu DNA polymerase (Stratagene) and specific oligonucleotide
primers with built-in NheI (59-end) and BamHI (39-end) restriction
sites. The BamHI site was preceded by a termination codon. Subcloning
of the blunt ended PCR fragment into SmaI-digested pGEM 3Z vector
allowed confirmation of sequence integrity. The fragment was excised
with NheI and BamHI and ligated into vector DNA to give pET-28a(1)
589–732a.
Two-hybrid Screening—Two-hybrid system reagents including the
mouse embryo cDNA library in pVP16, the S. cerevisiae reporter strain
L40, and screening methodology were as described previously (49, 52).
Briefly, S. cerevisiae L40 cells were transformed sequentially with
pBTM116-CyP40 185–370 and the library, and the yeast transformants
were plated on histidine-deficient medium. Of the 40 3 106 yeast
transformants screened, some 300 were identified as histidine pro-
totrophs of which 150 were selected for assessment of b-galactosidase
activity. 28 His1,LacZ1 colonies were grown in liquid medium deficient
in leucine and were used to generate crude plasmid DNA preparations.
These were transformed into competent Escherichia coli HB101 cells
allowing selection of colonies containing library hybrid plasmids. Puri-
fied minipreparations of the resultant clones were transformed into L40
yeast cells simultaneously with pBTM116-CyP40 185–370 bait plasmid,
and the transformants were assayed for b-galactosidase activity. To
reduce the risk of false positives, parallel transformations were per-
formed with individual library plasmids alone or in combination with
pBTM116,3 pBTM116-ARL-E1, and pBTM-LYN as negative controls.
cDNA inserts in library pVP16 plasmids, isolated from clones consid-
ered to be true positives, were sequenced using both a sense (59-
GAGTTTGAGCAGATGTTTA-39) and antisense M13 universal primer
(Applied Biosystems). 10 murine hsp84-related cDNAs (53) were recov-
ered from the true positive clones.
Protein Expression and Purification—The expression plasmid for
GST-bCyP40 WT fusion protein was transformed into E. coli strain
XL-1 Blue, and the protein was purified from lysates of bacterial cul-
tures by affinity chromatography on glutathione-agarose (Amersham
Pharmacia Biotech) as detailed previously (14). The expression plasmid
for FKBP52 was transformed in E. coli pVX28 (10). All other expression
constructs used in this study were transformed into E. coli BL21(DE3).
Recombinant CyP40, Hop, FKBP52, and hsp90b proteins were overex-
2 A. Carrello, manuscript in preparation. 3 E. Ingley, manuscript in preparation.
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pressed in bacterial cultures by induction with IPTG. Lysates were
prepared by sonicating bacterial cells in lysing buffer (CyP40, Hop: 10
mM Tris, pH 7.3, containing 100 mM KCl, 1 mM dithiothreitol, 0.2% v/v
Triton X-100, and 1 mg/ml lysozyme; FKBP52 and hsp90a and b: 50 mM
disodium hydrogen orthophosphate, pH 7.4, containing 300 mM NaCl, 10
mM imidazole, 1 mM dithiothreitol, 0.2% v/v Triton X-100, 1 mM phenyl-
methylsulfonyl fluoride, and 1 mg/ml lysozyme) and were cleared of par-
ticulate material by ultracentrifugation (100,000 3 g for 30 min at 4 °C).
For expression of His-tagged hsp90a and b deletion mutants, bacte-
rial cells harboring these clones were pelleted from overnight cultures
(150 ml) by centrifugation. After resuspension in 1.5 liters of fresh 2 YT
medium containing 200 mg/ml kanamycin, the bacteria were incubated
with shaking for a further 1 h at 37 °C. Protein expression was induced
with 1 mM IPTG over a 4-h period. Centrifugation gave a bacterial pellet
that was resuspended in 20 ml of lysing buffer (as described for
FKBP52, hsp90b). The freeze-thawed bacteria were sonicated on ice,
and the lysates were recovered by ultracentrifugation as already de-
scribed. All His-tagged recombinant proteins were purified from crude
lysates by chromatography on Ni-NTA-agarose (Qiagen). Unbound pro-
teins were removed from the chelate-agarose gel (0.5 ml) by 10 succes-
sive washes with 50 mM disodium hydrogen orthophosphate, pH 7.4
buffer, containing 300 mM NaCl, 10 mM imidazole, 1 mM dithiothreitol,
and 1 mM phenylmethylsulfonyl fluoride. The first wash also contained
1% v/v Triton X-100. Gel charged with immobilized His-tagged proteins
was stored at 4 °C for use in protein binding studies, or the absorbed
protein was recovered by elution with the same buffer (1 ml) containing
500 mM imidazole. Recovered proteins were assessed for purity by
SDS-PAGE with Coomassie Blue staining, and after equilibration by
dialysis against binding buffer (10 mM Tris pH 7.3, containing 100 mM
KCl and 1 mM dithiothreitol) they were stored in 200-ml aliquots at
270 °C until required.
Protein Binding Studies—Direct binding studies between wild-type
hsp90b and truncated hsp90 mutants with recombinant CyP40 and
Hop were conducted in parallel. Briefly, chelate-agarose gels containing
immobilized hsp90-related proteins were equalized for protein content
by diluting up to 3-fold with Sepharose 4B. The diluted gels were
prepared in duplicate 50-ml aliquots, and each set of duplicates was
rotated for 3 h at 4 °C with IPTG-induced bacterial lysates for CyP40
(150 ml) or Hop (200 ml). Both lysates had been equilibrated previously
in binding buffer plus 35 mM imidazole. The inclusion of imidazole to 35
mM concentration was found to be effective in limiting nonspecific
protein interaction with control chelate-agarose gel devoid of hsp90-
related proteins. The gels were subjected to replicate washes (8 3 500
ml) with binding buffer plus 35 mM imidazole, the first 5 washes being
supplemented with 0.2% v/v Triton X-100. Gel-retained proteins were
recovered by boiling in 40 ml of 2 3 SDS-PAGE sample buffer and then
analyzed by SDS-PAGE on 12.5% w/v polyacrylamide gel. Proteins were
visualized by Coomassie Blue staining.
In a reciprocal binding study, glutathione-agarose containing ab-
sorbed GST-bCyP40 WT fusion protein was diluted 5-fold with Sepha-
rose 4B, and 40-ml aliquots of the diluted gel were rotated separately for
3 h at 4 °C with 30 mg of the purified hsp90 truncated mutants equili-
brated in binding buffer (500 ml) containing 0.2% Triton X-100. After
pelleting by microcentrifugation, the gels were washed repeatedly as
already described, boiled in 2 3 SDS-PAGE sample buffer (40 ml), and
then examined for protein retention by SDS-PAGE.
To determine the binding preference of CyP40 for hsp90a versus
hsp90b, the diluted glutathione-agarose gel containing GST-bCyP40
WT fusion protein was suspended in 500 ml of binding buffer plus 0.2%
v/v Triton X-100, together with 30 mg of protein consisting of either
purified hsp90 530–724b or hsp90 589–732a alone or prepared in ratios
of 1:1, 5:1, and 1:5, respectively. After rotation for 3 h at 4 °C the gels
were washed free of unbound protein, boiled in 2 3 SDS-PAGE sample
buffer (40 ml), and assessed for retention of the hsp90a and b mutants
by SDS-PAGE.
The ability of Hop and FKBP52 to compete with CyP40 for binding to
the truncated mutant hsp90 581–724b was determined as follows. 0-,
20-, 50-, 100-, 200-, and 400-ml aliquots of induced Hop bacterial lysate
and 0-, 10-, 20-, 50-, 100-, and 200-ml aliquots of an extract containing
purified FKBP52 (concentration 0.54 mg/ml), were supplemented with
30 mg of purified hsp90 581–724b protein and the mixtures were
brought to 500-ml total volume with binding buffer containing 0.2% v/v
Triton X-100. After a 3-h preincubation period at 4 °C, the mixtures
were added to separate 40-ml aliquots of Sepharose 4B-diluted gluta-
thione-agarose containing immobilized GST-bCyP40 WT fusion protein.
After rotation at 4 °C for a further 3 h the gels were washed as de-
scribed, boiled with 40 ml of 2 3 SDS-PAGE sample buffer, and ana-
lyzed for hsp90 581–724b protein retention by SDS-PAGE with Coo-
massie Blue staining. Protein was quantitated by densitometric
scanning using Image Quant (Molecular Dynamics) software.
RESULTS
Isolation of Murine Hsp84 cDNAs Encoding a Distinct Inter-
action Domain for CyP40—We used a modification (49, 52) of
the yeast two-hybrid system (46) to isolate cDNA clones encod-
ing proteins that bind to the COOH-terminal half of CyP40.
This segment of CyP40 incorporates the TPR domain flanked
by acidic and basic subdomains at the NH2- and COOH-termi-
nal ends, respectively (14). The CyP40 COOH-terminal domain
was fused to the LexA DNA binding domain, and the resulting
FIG. 1. Murine (mhsp84) isolates
identified by two-hybrid genetic
screen with the COOH-terminal do-
main of CyP40. Hsp90 functional do-
mains for ATP/geldanamycin binding
(black) (43, 44, 70) and dimerization
(shaded) (56) are shown schematically.
Numbers refer to amino acid positions.
CyP40 interaction isolates, denoted by
amino acids (AA) 501–724, 517–724, and
558–724, are represented as narrow bars
(black).
FIG. 2. Structural domains of
hsp90b and hsp90 COOH-terminal
deletion mutants. Structural elements
for hsp90 include regions A, B, and Z (57–
59) and the MEEVD sequence motif at the
extreme COOH terminus (54). COOH-ter-
minal truncation mutants for hsp90a and
b isoforms are represented as narrow
bars (black).
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bait hybrid was used to screen a mouse embryo library of
hybrid proteins between the nuclear localized VP16 acidic ac-
tivation domain and random cDNA fragments. Size selection
for short cDNAs (; 500 nucleotides) facilitated rapid sequence
analysis and isolation of distinct protein interaction domains
within full-length polypeptides (52). Coexpression of the bait
and target hybrids into the yeast host S. cerevisiae L40 that
contains two integrated reporter constructs, the yeast HIS3
gene and the bacterial lacZ gene, allowed the isolation of
cDNAs coding for putative CyP40-interacting proteins. With
this approach, approximately 40 3 106 yeast transformants
were screened. More than 300 histidine-positive prototrophs
were detected, of which 150 were assayed qualitatively for the
presence of b-galactosidase activity. Transactivation of both
reporter constructs was observed in 28 transformants, from
which the library plasmids were isolated and subjected to false
positive analysis. These clones all interacted more strongly
with the CyP40 bait fusion protein than with several LexA
DNA-binding fusion controls. Sequence analysis of their cDNA
inserts revealed the presence of 10 incomplete murine hsp84
COOH-terminal clones, which fell into three distinct groups.
Seven inserts encoding residues 517–724 belonged to the most
predominant group. The remaining cDNAs encoded residues
501–724 (two clones) and 558–724 (one clone), respectively
(Fig. 1). These results strongly suggested that the COOH ter-
minus of hsp90 mediates binding to CyP40.
The Interaction Domain for CyP40 Is Located within the
124-residue Carboxyl-terminal Region of Hsp90, and Deletion
from the Carboxyl Terminus of Hsp90 Interferes with CyP40
Recognition—The mouse hsp84 sequence of those clones found
to interact most frequently with CyP40 differs from the equiv-
alent region of human hsp90b (53, 54) at only five residues.
Functional domains defined within hsp90 include a common
binding site for ATP/ADP and the antitumor agent geldanamy-
cin in the NH2 terminus (35, 36, 55) and a COOH-terminal
region that mediates hsp90 dimerization (56) (Fig. 1). Struc-
tural elements include highly charged a-helical regions A and
B and region Z, which resembles a heptad repeat domain char-
acteristic of leucine zippers (57–59) (Fig. 2). These structural
domains have been predicted to play a role in hsp90-protein
interaction (57–59).
Our results with the yeast two-hybrid system determined
that the interaction domain for CyP40 was confined to a 200-
residue COOH-terminal region of hsp90 corresponding to the
dimerization domain of the protein (Fig. 1). To confirm the
ability of this region to mediate CyP40 binding in vitro, we first
prepared the truncated deletion mutant hsp90 530–724b in-
corporating an NH2-terminal His-tag (Fig. 2). Pull-down assays
in which this protein was immobilized on Ni-NTA-agarose and
then exposed to bacterial lysate containing wild-type bCyP40
showed avid retention of the cyclophilin (Fig. 3A, lane 2). More-
over, in mapping studies (not shown) conducted with a series of
GST-fusion proteins incorporating wild-type bCyP40 and sev-
eral CyP40 deletion mutants, the hsp90 530–724b protein dis-
played an interaction pattern identical to that described previ-
ously for full-length hsp90b (14). This COOH-terminal segment
of hsp90 therefore appears to contain all of the essential ele-
ments for CyP40-hsp90 interaction.
We then prepared sequential NH2-terminal and COOH-ter-
minal deletions of this original construct to delineate further
the interaction domain for CyP40 (Fig. 2). The design of these
additional mutants was guided by information from available
reports (57–59) describing the microdomain structure within
the hsp90 COOH-terminal region (Fig. 2). For example, the
construct hsp90 581–724b was prepared to assess the role of
the hydrophilic region B in the hsp90-CyP40 interaction. The
EEVD motif, which is conserved at the extreme COOH termi-
nus in both the hsp70 and hsp90 molecular chaperone families
(54, 60), has been shown to have an important regulatory role
in hsp70 function (60). Preparation of the hsp90 530–719b
construct was aimed at testing the influence of this regulatory
motif on hsp90 recognition of CyP40. Although hsp90a and b
appear to be equivalent in the context of steroid receptor and
immunophilin interaction (61), we also prepared hsp90 589–
732a to allow a direct comparison with hsp90 581–724b for
CyP40 binding efficiency.
The ability of these truncated proteins to bind CyP40 was
examined in pull-down assays in which chelate-agarose
charged with equal amounts of wild-type hsp90b and the re-
combinant deletion mutants was incubated with bacterial ly-
sates containing wild-type CyP40. Our binding profiles showed
that the hsp90 530–724b, 581–724b, and 600–724b proteins
FIG. 3. Binding properties of wild-type hsp90b and hsp90a and b COOH-terminal truncation mutants to CyP40. Panel A, chelate-
agarose gels (50 ml) charged with His-tagged hsp90-related proteins were mixed with rotation for 3 h at 4 °C with IPTG-induced bacterial lysate
(150 ml) for full-length bCyP40 in binding buffer containing 35 mM imidazole. After centrifugation, the gels were washed repeatedly with the same
buffer, initially supplemented with 0.2% v/v Triton X-100. Gel-retained proteins were recovered with SDS-PAGE sample buffer and analyzed on
a 12.5% w/v polyacrylamide gel followed by Coomassie Blue staining. Protein molecular weight markers (Amersham Pharmacia Biotech) are shown
on the left side. Panel B, glutathione-agarose gels (40 ml) charged with GST-bCyP40 WT fusion protein were rotated separately for 3 h at 4 °C with
purified hsp90 truncated mutants (30 mg) in binding buffer (500 ml) containing 0.2% v/v Triton X-100. After microcentrifugation and replicate
washing, gel-bound protein was recovered with SDS-PAGE sample buffer and analyzed as described for panel A.
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(Fig. 3A, lanes 2, 3, and 4) bound CyP40 with high efficiency.
Removal of the 24-residue segment at the extreme COOH ter-
minus of hsp90 (construct 530–700b) completely abolished
CyP40 binding (Fig. 3A, lane 6). Remarkably, the mutant 530–
719b, in which the last five residues MEEVD of hsp90b are
deleted, was also unable to interact with CyP40 (Fig. 3A, lane
5). The above results were corroborated by a reciprocal study in
which the hsp90 deletion mutants were incubated separately
with GST-bCyP40 WT fusion protein immobilized on gluta-
thione-agarose (Fig. 3B). Our results located the binding site
for CyP40 to a 124-residue COOH-terminal region of hsp90
and suggested that the presence of the EEVD motif at the
extreme COOH terminus of hsp90 is critical for CyP40-hsp90
interaction.
The results of Fig. 3, A and B, also indicated that the 581–
724b and 589–732a deletion mutants were capable of efficient
interaction with wild-type CyP40. A more rigorous examina-
tion of the possible preference of CyP40 for one or other of the
hsp90a or b isoforms was conducted in a separate study. Anal-
ysis was facilitated by the use of chelate-agarose-purified
hsp90 530–724b and hsp90 589–732a deletion mutants, which
allowed SDS-PAGE discrimination on the basis of size. Fig. 4
shows the results of a binding study in which GST-bCyP40 WT,
immobilized on glutathione-agarose, was exposed to extracts
containing either recombinant hsp90 530–724b (lane 1) or
hsp90 589–732a (lane 2) alone or to mixtures in which the
ratios of the respective isoforms were 1:1 (lane 3), 5:1 (lane 4),
and 1:5 (lane 5). It was apparent from the observed binding
profiles that CyP40 does not display an affinity for one hsp90
isoform over the other.
CyP40, FKBP52, and Hop Interact with Hsp90 via a Com-
mon Domain within the Hsp90 Carboxyl Terminus—Evidence
that Hop and FKBP52 compete directly with CyP40 for hsp90
binding has led to proposals that these proteins might target a
common or overlapping site within hsp90 (44). It was of inter-
est therefore to test the ability of Hop and FKBP52 to bind to
the COOH-terminal region of hsp90 which we had determined
to be important for CyP40-hsp90 interaction. Fig. 5 shows that
incubation of our panel of hsp90 deletion mutants, immobilized
on chelate-agarose, with Hop bacterial lysates produced a re-
tention profile that closely resembled the pattern observed with
CyP40 (Fig. 3A). The result is consistent with the presence of
common binding elements for CyP40 and Hop within a discrete
carboxyl-terminal domain of hsp90. We next examined the
ability of FKBP52 and Hop to compete with CyP40 for binding
to hsp90 581–724b. Extracts containing the purified hsp90
deletion construct were preincubated with increasing amounts
of purified FKBP52 or Hop bacterial lysate. After addition of
glutathione-agarose charged with GST-bCyP40 WT fusion pro-
tein, the mixtures were incubated for a further period, and the
gels were then assessed for retention of hsp90 581–724b by
SDS-PAGE. Fig. 6 shows that increasing concentrations of
FKBP52 caused a progressive reduction in the relative amount
of the hsp90 deletion mutant retained by gel-immobilized
CyP40. Similar competitive binding was observed with Hop
(not shown). Together the results confirmed that CyP40,
FKBP52, and Hop interact directly with a common domain in
hsp90 581–724b.
DISCUSSION
A search for cellular protein targets for the CyP40 COOH-
terminal protein-interaction domain (amino acids 185–370),
using the yeast two-hybrid method, resulted in the cloning of
cDNAs encoding hsp90 with an intact carboxyl terminus. The
overlapping region common to these cDNAs corresponded to
amino acids 558–724 of human hsp90b. To confirm this inter-
action in vitro, the deletion mutant hsp90 530–724b, contain-
ing an NH2-terminal histidine tag, was immobilized on chelate-
agarose gel and shown to retain wild-type bCyP40 specifically.
Pull-down assays with recombinant hsp90 530–724b and GST-
CyP40 deletion mutants on glutathione-agarose revealed a
binding profile similar to that determined previously for full-
length hsp90 (14), suggesting that the COOH-terminal hsp90
segment contains the essential binding elements for CyP40-
hsp90 interaction.
Binding analyses with sequential NH2-terminal deletion mu-
tants of the hsp90 530–724b protein showed the recognition
site for CyP40 to be located within a 124-residue, COOH-
terminal region of hsp90. A deletion mutant truncated from the
COOH-terminal end by deleting the pentapeptide MEEVD was
unable to bind CyP40, highlighting the critical importance of
this conserved motif for CyP40-hsp90 interaction. Under the
same conditions, the interaction profile of Hop for the hsp90
derivatives closely matched that displayed by CyP40. This,
together with evidence of direct competition of Hop and
FKBP52 with CyP40 for binding to hsp90 581–724b protein,
supports the existence of a common TPR interaction site for
Hop and the immunophilins within a discrete COOH-terminal
domain of hsp90. It is possible, however, that additional re-
gions in hsp90, lying outside of this general TPR acceptor site,
contribute to stabilize the interaction between hsp90 and its
cochaperone partners (16). Our data extend the findings of
recent reports by Chen et al. (16) and by Young et al. (63) that
Hop and the steroid receptor-associated immunophilins bind to
the COOH-terminal region of hsp90.
After a comprehensive assessment of the effect of mutations
FIG. 4. CyP40 does not show a bind-
ing preference for hsp90a or b iso-
forms. Glutathione-agarose gels charged
with GST-bCyP40 WT fusion protein
were incubated as described in the Fig.
3B legend with 30 mg of purified hsp90
530–724b or hsp90 589–732a alone or
prepared in ratios of 1:1, 5:1, and 1:5,
respectively. After replicate washing to
remove unbound protein, the gels were
boiled in SDS-PAGE sample buffer, and
recovered proteins were analyzed by
SDS-PAGE.
The TPR Acceptor Site of Hsp902686
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
throughout chicken hsp90a on hsp90 interaction with acces-
sory proteins, Chen et al. (16) have been able to provide de-
tailed comparisons between the hsp90 binding requirements
for Hop, the TPR-containing immunophilins, and p23. Replace-
ment of the EEVD motif by AAVD, at the extreme COOH
terminus of hsp90, reduced hsp90 interactions for all of the
TPR proteins, with binding being all but eliminated for CyP40
and Hop (16). The interactions of hsp90 with FKBP52 and
FKBP51 were less sensitive to this mutation, with significant
binding levels being maintained (16). Our study, in which the
hsp90 mutant deleted in the MEEVD peptide failed to recog-
nize both CyP40 and Hop, is consistent with the findings of
Chen et al. (16). It is possible that, as in hsp70 (60), the
conserved EEVD motif might contribute to the overall confor-
mation of the hsp90 protein and have a role in the intramolec-
ular regulation of hsp90 function.
Our study has demonstrated conclusively that CyP40 does
not have a binding preference for either hsp90a or b. From
heat-induced dissociation experiments with FKBP52zhsp90
complexes, Czar et al. (61) noted previously that neither of the
isoforms is dissociated selectively, suggesting that FKBP52
may bind equivalently with each hsp90 subtype. The isoforms
are produced in equal amounts in higher eukaryotes (64) and
share an 86% homology, differing at 99 residues in their amino
acid sequences (54). A glutamate-rich segment within the NH2-
terminal sequence distinguishes the hsp90a class from hsp90b
homologs (54). Heat shock induces a more profound increase in
hsp90a expression compared with hsp90b, and only hsp90a is
induced by adenovirus E1A (65). Despite these differences,
virtually identical hydropathy plots for the isoforms indicate a
high degree of structural similarity (54). It is of interest, how-
ever, that the hsp90 species associated with chicken steroid
receptors (66) and that isolated with the bovine estrogen recep-
tor (67) have both been identified as a isoforms.
We have examined the 124-residue COOH-terminal se-
quence that incorporates the TPR acceptor site in hsp90 to
identify structural elements with potential to mediate hsp90
interaction with TPR proteins. Charge distribution within this
domain is highly conserved between human hsp90a and b (54)
and in chicken hsp90a (66) and mouse hsp84 (53). Taking this
charge distribution into account, we divided the binding region
in hsp90b into two subdomains (Fig. 7). A highly acidic region
is located at the carboxyl terminus (amino acids 691–724, 1
basic and 15 acidic residues) and includes the EEVD motif,
deletion of which abrogates hsp90-TPR protein binding. An
essentially neutral subdomain (amino acids 600–690, 16 basic
and 12 acidic residues), which is characterized by a repeated
helix-coil-helix secondary structure (57), contains a concentra-
tion of charged residues between amino acids 623–653 (9 basic
and 7 acidic residues) (54). This hydrophilic domain sits adja-
cent to a hydrophobic region (amino acids 657–673 in human
hsp90b, equivalent to amino acids 661–677 in chicken hsp90a)
which is necessary for hsp90 dimerization (68). Chen et al. (16)
have also shown that deletion of this 16-residue segment
causes a marked reduction in the binding of hsp90 to Hop and
the steroid receptor-associated immunophilins. Removal of this
critical domain disrupts a predicted a-helical structure (57),
possibly resulting in conformational changes unfavorable for
dimerization and TPR-protein interaction.
Several points of evidence suggest that the interaction site
for Hop and the TPR immunophilins lies within the dimeriza-
tion domain of hsp90. Dimerization is an intrinsic property of
hsp90, required for its biological function in intact cells (69).
Nemoto et al. (56, 70) have demonstrated that the ability of
hsp90 to dimerize and to form higher order oligomers resides in
the COOH-terminal 200 amino acids. Furthermore, the same
workers have proposed that dimerization of hsp90a is mediated
by the interaction of one subdomain (defined by residues 542–
615) with a different subregion (residues 621–698) of a second
hsp90 subunit (56, 71). Such a mechanism is compatible with
the observed sensitivity of hsp90-TPR protein interaction to
deletions within these specific regions (16).
Evidence suggests that within steroid receptor heterocom-
plexes the stoichiometry is defined by single molecules of re-
ceptor, p23 and one of the immunophilins together with dimeric
hsp90 (61). Although we have not determined whether our
hsp90b mutants exist as dimers or monomers, the protein
hsp90 600–724b is largely deficient in sequences thought nec-
essary for dimerization (56, 71) and is therefore likely to be
monomeric. Efficient binding of both CyP40 and Hop to this
FIG. 5. Interaction properties of wild-type hsp90b and hsp90a
and b COOH-terminal truncation mutants with Hop. Chelate-
agarose gels (50 ml) charged with His-tagged hsp90-related proteins
were rotated for 3 h at 4 °C with IPTG-induced bacterial lysate (200 ml)
for Hop in binding buffer containing 35 mM imidazole. After microcen-
trifugation and replicate washing, the gels were assessed for bound Hop
by SDS-PAGE as described in the Fig. 3A legend.
FIG. 6. FKBP52 competition with CyP40 for binding to hsp90
581–724b. Aliquots (0, 10, 20, 50, 100, and 200 ml) of purified FKBP52
extract (FKBP52 concentration 0.54 mg/ml) were supplemented with
purified hsp90 581–724b protein (30 mg) and were equalized to 500 ml
with binding buffer plus 0.2% v/v Triton X-100. After brief mixing, the
samples were preincubated for 3 h at 4 °C and then added to separate
40-ml aliquots of glutathione-agarose charged with GST-bCyP40 WT
fusion protein. After rotation at 4 °C for a further 3 h, the gels were
washed as in Fig. 3B and analyzed for retained hsp90 581–724b by
SDS-PAGE as already described.
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mutant suggests that both proteins are capable of interacting
with a monomer of hsp90.
Shaknovich et al. (72) provided initial evidence that the
COOH-terminal domain of hsp90 might have a biological func-
tion beyond that of dimer formation. They described the con-
version of the basic helix-loop-helix transcription factor MyoD
to a form with enhanced DNA binding activity through a tran-
sient interaction with a recombinant protein containing the
COOH-terminal 194 residues of hsp90 (72). This conforma-
tional activation of MyoD occurred without the requirement of
ATP (72) and was extended to other basic helix-loop-helix pro-
teins (73). A recent analysis of human hsp90a NH2-terminal
(residues 9–236) and COOH-terminal (residues 629–732) do-
mains has confirmed independent chaperone activities within
these sites (74, 75). In full-length hsp90, the sites appear to
contribute independently to chaperone activity, differing in
substrate specificity and nucleotide dependence (74, 75). The
presence of chaperone and dimerization functions within a
discrete hsp90 COOH-terminal domain, which also mediates
interactions with TPR cochaperone proteins, is intriguing. It is
possible then that hsp90 partner proteins, such as Hop and the
TPR-containing immunophilins, might have an important
modulating role in hsp90 function (38).
Data from mutational analyses of hsp90 binding to steroid
receptors are consistent with the COOH-terminal half of hsp90
being involved in receptor interaction and in the maintenance
of receptor biological function (64). Certain regions within
hsp90 appear to have a differential effect on hsp90-steroid
receptor interaction and on the activity of individual receptor
systems (59, 68, 76, 77), highlighting the diversity among the
receptors. Deletion of the acidic region A (residues 221–290)
precluded the interaction of chicken hsp90a with the glucocor-
ticoid receptor (59), but recognition of the progesterone (76) and
estrogen receptors (68) was unaffected. Critical regions for
hsp90-progesterone receptor binding are located between resi-
dues 381 and 441, and 601 and 677 of chicken hsp90a (76). The
first incorporates the leucine heptad repeat region Z (59), and
the second overlaps the hsp90 dimerization domain (56). Dele-
tions that compromise the in vivo interaction of hsp90 with the
estrogen receptor include those that correspond to region Z and
the charged region B (residues 521–567). Additional elements
implicated in hsp90 association with the estrogen receptor are
contained between residues 601 and 620, and 698 and 728 (68).
The latter defines the acidic subdomain at the carboxyl termi-
nus of hsp90 (57, 66). Its deletion results in the loss of hsp90
dimerization (68). Deletion of the hydrophobic sequence be-
tween residues 661 and 677 also disrupts hsp90 dimer forma-
tion, but this segment appears to be dispensable for hsp90-
estrogen receptor interaction (68).
Hsp90 functions as a dimer and is divisible into three func-
tional domains (Fig. 8). The NH2-terminal domain harbors a
common site for ATP binding and interaction with geldanamy-
cin and has a chaperone activity that is modulated by both
agents (35, 36, 55, 74, 75). An ATP-independent chaperone
function exists in the COOH-terminal domain, a region that
also appears to be critically important for hsp90 dimerization
(56, 68, 70, 71) and binding of client proteins such as steroid
receptors (64, 68, 76, 77). Our results show that this domain is
also a target for the TPR-containing immunophilins and Hop. A
central charged domain may provide additional elements that
contribute to stabilizing the dimeric form of hsp90 (36) as well
as interactions with steroid receptors (57–59) and hsp90 part-
ner proteins (16). Identification of an ATP binding site within
hsp90 has led to proposals that in response to ATP binding and
hydrolysis, hsp90 may undergo changes in conformation in a
manner analogous to hsp70 (36). Indeed, evidence suggests
that these conformational changes are translated throughout
the hsp90 protein (34–38) and may involve the MEEVD pep-
tide at the hsp90 COOH terminus (16). Thus only the ATP-
bound state of hsp90 interacts with p23 (34). Nucleotide ex-
FIG. 8. Hsp90 functional domains. The NH2-terminal sequence (residues 1–221) incorporates a chaperone function (74, 75) and binding sites
for geldanamycin and ATP (35, 36, 55). A dimerization domain (residues 524–724) exists at the COOH-terminal end of hsp90 (56). This overlaps
a region (residues 621–724) that elicits a chaperone function (74, 75) and the ability to interact with TPR proteins. A large segment (residues
221–724) includes elements that mediate association with steroid receptors (64, 68, 76, 77).
FIG. 7. Structure of the TPR inter-
action domain in hsp90. The TPR ac-
ceptor site of hsp90b is located within a
COOH-terminal region spanning amino
acid residues 600–724. Acidic and basic
residues are highlighted by negative and
positive charges, respectively. Within this
sequence exists an acidic domain, defined
by residues 690–724, which includes the
EEVD sequence motif at the extreme
COOH terminus. A 50-residue segment
(623–673) incorporates a hydrophilic do-
main adjacent to a hydrophobic region
(residues 653–673) and includes two pre-
dicted a-helical microdomains (57).
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change to the ADP-bound form stabilizes a hydrophobic surface
in hsp90 (34, 35) which may facilitate interaction with protein
substrates (34–38). Hop binds preferentially to ADP-bound
hsp90 and blocks ATP-dependent conversion to a form capable
of interaction with p23 (37).
It is possible that the interaction between hsp90 and differ-
ent target substrates is governed by different cochaperones
(38). The three immunophilins CyP40, FKBP51, and FKBP52
then might modulate the function of hsp90 either by altering
hsp90 conformation or by influencing ATP binding and the
ability of hsp90 to recognize and interact with unfolded sub-
strate proteins (34, 38). A precedent for such controlling influ-
ences over hsp90 has been set by the ability of CyP40 to inhibit
c-Myb DNA binding activity via a mechanism that requires
both the CyP40 protein interaction domain and its peptidyl-
prolyl isomerase function (62). In an alternate model, hsp90
may provide a scaffold for TPR proteins, allowing them to
locate close to hsp90 chaperone substrates. From such a posi-
tion the immunophilins CyP40, FKBP51, and FKBP52 might
act directly on steroid receptors to modulate receptor activity
through an independent chaperone function (39, 40).
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